L Kocik1, H Geinitz2, C Track2, M Geier2, C Nieder3,4. 1. Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, 4010, Linz, Austria. lukas.kocik@ordensklinikum.at. 2. Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, 4010, Linz, Austria. 3. Department of Oncology and Palliative Medicine, Nordland Hospital Trust, 8092, Bodø, Norway. 4. Department of Clinical Medicine, Faculty of Health Sciences, UiT-The Arctic University of Norway, 9037, Tromsø, Norway.
Abstract
PURPOSE: Specific information about radiation therapy in nonagenarians is limited. In order to shed more light on the feasibility of radiotherapy in this challenging subgroup, a retrospective study was performed. METHODS: The data of 93 consecutive patients receiving irradiation treatment at the Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern between June 2005 and December 2016 were analyzed. Patient- and treatment-related factors were extracted from the patient records. Overall survival (OS) was defined as time from irradiation to death or last follow-up. The survival rates were analyzed using the Kaplan-Meier method and log-rank test. RESULTS: The study population of 93 patients was between 90 and 99 years old (median 91 years). It included 59 women (63%) and 34 men (37%). Of these, 38 (41%) received definitive radiotherapy, 14 (15%) received neoadjuvant or adjuvant radiotherapy, whereas a palliative regimen was prescribed in 44% of the cases (n = 41). In all, 79 patients (85%) were able to complete their prescribed course of radiotherapy. While 16 (17%) patients reported grade 2 toxicities or higher, 4 had ≥grade 3 side effects (4%). The median survival was significantly higher in patients treated with adjuvant, neoadjuvant or definitive radiotherapy (13.8 months) compared to patients treated with palliative radiotherapy (3.6 months; p < 0.001). CONCLUSION: Even in patients managed without preradiotherapy comprehensive geriatric assessment, carefully planned fractionated radiotherapy was feasible and resulted in acceptable rates of acute toxicities.
PURPOSE: Specific information about radiation therapy in nonagenarians is limited. In order to shed more light on the feasibility of radiotherapy in this challenging subgroup, a retrospective study was performed. METHODS: The data of 93 consecutive patients receiving irradiation treatment at the Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern between June 2005 and December 2016 were analyzed. Patient- and treatment-related factors were extracted from the patient records. Overall survival (OS) was defined as time from irradiation to death or last follow-up. The survival rates were analyzed using the Kaplan-Meier method and log-rank test. RESULTS: The study population of 93 patients was between 90 and 99 years old (median 91 years). It included 59 women (63%) and 34 men (37%). Of these, 38 (41%) received definitive radiotherapy, 14 (15%) received neoadjuvant or adjuvant radiotherapy, whereas a palliative regimen was prescribed in 44% of the cases (n = 41). In all, 79 patients (85%) were able to complete their prescribed course of radiotherapy. While 16 (17%) patients reported grade 2 toxicities or higher, 4 had ≥grade 3 side effects (4%). The median survival was significantly higher in patients treated with adjuvant, neoadjuvant or definitive radiotherapy (13.8 months) compared to patients treated with palliative radiotherapy (3.6 months; p < 0.001). CONCLUSION: Even in patients managed without preradiotherapy comprehensive geriatric assessment, carefully planned fractionated radiotherapy was feasible and resulted in acceptable rates of acute toxicities.
Authors: Brian N Arnold; Daniel C Thomas; Joshua E Rosen; Michelle C Salazar; Frank C Detterbeck; Justin D Blasberg; Daniel J Boffa; Anthony W Kim Journal: Surgery Date: 2017-07-08 Impact factor: 3.982
Authors: Aimee Thompson; Rebecca Cone; Helen Gao; Elizabeth Hammond; David Fraser; Michael F Back Journal: Asia Pac J Clin Oncol Date: 2012-03-12 Impact factor: 2.601
Authors: D Franceschini; F De Rose; L Cozzi; P Navarria; E Clerici; C Franzese; T Comito; A Tozzi; C Iftode; G D'Agostino; M Sorsetti Journal: Strahlenther Onkol Date: 2017-02-06 Impact factor: 3.621
Authors: Richard J Cassidy; Pretesh R Patel; Xinyan Zhang; Robert H Press; Jeffrey M Switchenko; Rathi N Pillai; Taofeek K Owonikoko; Suresh S Ramalingam; Felix G Fernandez; Seth D Force; Walter J Curran; Kristin A Higgins Journal: Clin Lung Cancer Date: 2017-03-16 Impact factor: 4.785
Authors: Claudia Andrä; Alexander Klein; Hans Roland Dürr; Josefine Rauch; Lars Hartwin Lindner; Thomas Knoesel; Martin Angele; Andrea Baur-Melnyk; Claus Belka; Falk Roeder Journal: Strahlenther Onkol Date: 2017-02-22 Impact factor: 3.621
Authors: V Bouzereau; F Le Caer; E Guardiola; C Scavennec; J R Barriere; L Chaix; H Le Caer Journal: J Geriatr Oncol Date: 2013-05-21 Impact factor: 3.599
Authors: Daniel Buergy; Victor Siefert; Christian Neumaier; Thomas Ganslandt; Elena Sperk; Manuel Blessing; Jürgen Hesser; Grit Welzel; Frederik Wenz; Frank Anton Giordano Journal: Strahlenther Onkol Date: 2019-11-18 Impact factor: 3.621
Authors: Erik Haehl; Alexander Rühle; Simon Spohn; Tanja Sprave; Eleni Gkika; Constantinos Zamboglou; Anca-Ligia Grosu; Nils H Nicolay Journal: Front Oncol Date: 2022-01-03 Impact factor: 6.244